Tacrolimus - Selten Pharma

Drug Profile

Tacrolimus - Selten Pharma

Alternative Names: SPI-026

Latest Information Update: 27 Jan 2017

Price : $50

At a glance

  • Originator Selten Pharma; Stanford University
  • Developer Selten Pharma
  • Class Lactones; Macrolides
  • Mechanism of Action Bone morphogenetic protein receptor type II modulators; Calcineurin inhibitors; Cytokine inhibitors; T cell activation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pulmonary arterial hypertension
  • New Molecular Entity No

Highest Development Phases

  • Phase II Pulmonary arterial hypertension

Most Recent Events

  • 09 Jan 2017 Tacrolimus licensed to VIVUS worldwide for the treatment of Pulmonary arterial hypertension
  • 09 Jan 2017 Selton assigns its license to patents owned by Stanford University and all rights to patent applications owned by Selten to VIVUS
  • 15 Mar 2016 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top